 Tumor Necrosis Factor-alpha
"Tumor Necrosis Factor-alpha" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS.
| Descriptor ID |
D014409
|
| MeSH Number(s) |
D12.644.276.374.500.800 D12.644.276.374.750.626 D12.644.276.972.626 D12.776.124.900 D12.776.395.930 D12.776.467.374.500.800 D12.776.467.374.750.626 D12.776.467.972.626 D23.529.374.500.800 D23.529.374.750.626 D23.529.972.626
|
| Concept/Terms |
Tumor Necrosis Factor-alpha- Tumor Necrosis Factor-alpha
- Tumor Necrosis Factor alpha
- Cachectin-Tumor Necrosis Factor
- Cachectin Tumor Necrosis Factor
- TNFalpha
- TNF-alpha
- Tumor Necrosis Factor
- Tumor Necrosis Factor Ligand Superfamily Member 2
- Cachectin
- TNF Superfamily, Member 2
|
Below are MeSH descriptors whose meaning is more general than "Tumor Necrosis Factor-alpha".
Below are MeSH descriptors whose meaning is more specific than "Tumor Necrosis Factor-alpha".
This graph shows the total number of publications written about "Tumor Necrosis Factor-alpha" by people in this website by year, and whether "Tumor Necrosis Factor-alpha" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1987 | 1 | 0 | 1 | | 1988 | 4 | 0 | 4 | | 1989 | 4 | 3 | 7 | | 1990 | 7 | 3 | 10 | | 1991 | 10 | 2 | 12 | | 1992 | 6 | 5 | 11 | | 1993 | 2 | 3 | 5 | | 1994 | 6 | 4 | 10 | | 1995 | 11 | 7 | 18 | | 1996 | 6 | 3 | 9 | | 1997 | 4 | 5 | 9 | | 1998 | 2 | 7 | 9 | | 1999 | 4 | 12 | 16 | | 2000 | 4 | 7 | 11 | | 2001 | 10 | 10 | 20 | | 2002 | 13 | 10 | 23 | | 2003 | 11 | 12 | 23 | | 2004 | 19 | 16 | 35 | | 2005 | 8 | 10 | 18 | | 2006 | 10 | 15 | 25 | | 2007 | 15 | 15 | 30 | | 2008 | 6 | 14 | 20 | | 2009 | 10 | 9 | 19 | | 2010 | 7 | 13 | 20 | | 2011 | 8 | 15 | 23 | | 2012 | 10 | 19 | 29 | | 2013 | 11 | 6 | 17 | | 2014 | 4 | 11 | 15 | | 2015 | 5 | 13 | 18 | | 2016 | 2 | 9 | 11 | | 2017 | 7 | 9 | 16 | | 2018 | 4 | 9 | 13 | | 2019 | 4 | 8 | 12 | | 2020 | 2 | 11 | 13 | | 2021 | 0 | 8 | 8 | | 2022 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Tumor Necrosis Factor-alpha" by people in Profiles.
-
De T, Zhang H, Alarcon C, Lec B, Avitia J, Smithberger E, Chen C, Horvath M, Kwan S, Young M, Adhikari S, Kwon J, Pacheco J, Jarvik G, Wei WQ, Mentch F, Hakonarson H, Sleiman P, Gordon A, Harley J, Linneman J, Hebbring S, Parisiadou L, Perera MA. Genetic association of primary nonresponse to anti-TNFa therapy in patients with inflammatory bowel disease. Pharmacogenet Genomics. 2022 01 01; 32(1):1-9.
-
Shen B, Kochhar GS, Rubin DT, Kane SV, Navaneethan U, Bernstein CN, Cross RK, Sugita A, Schairer J, Kiran RP, Fleshner P, McCormick JT, D'Hoore A, Shah SA, Farraye FA, Kariv R, Liu X, Rosh J, Chang S, Scherl E, Schwartz DA, Kotze PG, Bruining DH, Philpott J, Abraham B, Segal J, Sedano R, Kayal M, Bentley-Hibbert S, Tarabar D, El-Hachem S, Sehgal P, Picoraro JA, Vermeire S, Sandborn WJ, Silverberg MS, Pardi DS. Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium. Lancet Gastroenterol Hepatol. 2022 01; 7(1):69-95.
-
Bressler B, Yarur A, Silverberg MS, Bassel M, Bellaguarda E, Fourment C, Gatopoulou A, Karatzas P, Kopylov U, Michalopoulos G, Michopoulos S, Navaneethan U, Rubin DT, Siffledeen J, Singh A, Soufleris K, Stein D, Demuth D, Mantzaris GJ. Vedolizumab and Anti-Tumour Necrosis Factor a Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study. J Crohns Colitis. 2021 Oct 07; 15(10):1694-1706.
-
Akiyama S, Cotter TG, Sakuraba A. Risk of hepatitis B virus reactivation in patients with autoimmune diseases undergoing non-tumor necrosis factor-targeted biologics. World J Gastroenterol. 2021 May 21; 27(19):2312-2324.
-
Kunz HE, Hart CR, Gries KJ, Parvizi M, Laurenti M, Dalla Man C, Moore N, Zhang X, Ryan Z, Polley EC, Jensen MD, Vella A, Lanza IR. Adipose tissue macrophage populations and inflammation are associated with systemic inflammation and insulin resistance in obesity. Am J Physiol Endocrinol Metab. 2021 07 01; 321(1):E105-E121.
-
Cui YH, Yang S, Wei J, Shea CR, Zhong W, Wang F, Shah P, Kibriya MG, Cui X, Ahsan H, He C, He YY. Autophagy of the m6A mRNA demethylase FTO is impaired by low-level arsenic exposure to promote tumorigenesis. Nat Commun. 2021 04 12; 12(1):2183.
-
Reid PD, Cifu AS, Bass AR. Management of Immunotherapy-Related Toxicities in Patients Treated With Immune Checkpoint Inhibitor Therapy. JAMA. 2021 Feb 02; 325(5):482-483.
-
Kimani FW, Ajit J, Galluppi A, Manna S, Howitz WJ, Tang S, Esser-Kahn AP. Receptor-Ligand Kinetics Influence the Mechanism of Action of Covalently Linked TLR Ligands. ACS Chem Biol. 2021 02 19; 16(2):380-388.
-
Son M, Wang AG, Tu HL, Metzig MO, Patel P, Husain K, Lin J, Murugan A, Hoffmann A, Tay S. NF-?B responds to absolute differences in cytokine concentrations. Sci Signal. 2021 01 19; 14(666).
-
Chakraborty S, Gonzalez J, Edwards K, Mallajosyula V, Buzzanco AS, Sherwood R, Buffone C, Kathale N, Providenza S, Xie MM, Andrews JR, Blish CA, Singh U, Dugan H, Wilson PC, Pham TD, Boyd SD, Nadeau KC, Pinsky BA, Zhang S, Memoli MJ, Taubenberger JK, Morales T, Schapiro JM, Tan GS, Jagannathan P, Wang TT. Proinflammatory IgG Fc structures in patients with severe COVID-19. Nat Immunol. 2021 01; 22(1):67-73.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|